C3G
Clinical trials for C3G explained in plain language.
Never miss a new study
Get alerted when new C3G trials appear
Sign up with your email to follow new studies for C3G, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug trial targets rare kidney diseases
Disease control Recruiting nowThis study is testing an experimental drug called ADX-038 for people with specific immune-related kidney diseases. Researchers will enroll 45 adults with conditions like IgA nephropathy or C3 glomerulopathy to see if the drug is safe and helps control their kidney disease. The go…
Matched conditions: C3G
Phase: PHASE2 • Sponsor: ADARx Pharmaceuticals, Inc. • Aim: Disease control
Last updated Mar 30, 2026 14:32 UTC
-
Breakthrough drug trial aims to halt rare kidney disease progression
Disease control Recruiting nowThis study is testing whether the drug iptacopan can help control a rare kidney disease called C3G. About 98 patients aged 12-60 will receive either the drug or a placebo for 6-12 months, along with their standard care. Researchers will check if the drug reduces protein in urine,…
Matched conditions: C3G
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Mar 16, 2026 15:25 UTC